-
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024. At the conference, management will discuss its novel MagnetOs portfolio of products and its application to spinal fusion. Presentation details are as follows: Presenter: Chris Fair, Chief Executive Officer of Kuros Biosciences Presentation time: 10:00 am – 10:25 am EDT Location: Colonial Room Additional executive leadership team members in attendance: Daniel Geiger, Chief Financial Officer and Joost de Bruijn, Executive Director and President of Innovation and Strategy A replay of the presentation will be available…
-
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs Granules and MagnetOs Putty in New Zealand via an exclusive distribution agreement with Vortek Spine Limited, a high-tech orthopedic and biologics company Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced clearance of a 510(k) submission from the U.S. Food and Drug Administration (FDA) related to its MagnetOs™ Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek…
-
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging posterior spinal fusion approach, demonstrates a fusion rate of 78% versus 45% after one year In the difficult-to-treat patient population of smokers, MagnetOs demonstrates impressive 80% fusion rate compared to 32% fusion rate with autograft (intrapatient control) MagnetOs Easypack Putty becomes the second product in the MagnetOs portfolio to receive FDA clearance to market for interbody use MagnetOs Putty receives FDA clearance for standalone use and can now be used without the need for autograft Kuros Biosciences, a leader in next generation bone graft technologies, announced today three advancements…
-
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE trial, MagnetOs mixed with autograft showed posterolateral fusion rates comparable to autograft fusion rates in the less challenging interbody space In the STRUCTURE trial, according to an interim analysis, Fibrin-PTH did not outperform autograft for interbody fusion, although patients showed excellent clinical outcomes Considering the outstanding clinical results of MagnetOs in the MAXA and STRUCTURE trials, and the recent FDA interbody clearance, Kuros has decided not to proceed to Phase 3 with Fibrin-PTH and focus its resources on MagnetOs …
-
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used on-label in any interbody cage cleared for use with a bone void filler The exceptional handling properties of MagnetOs Flex Matrix are uniquely applicable to interbody applications Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for…
-
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in the same period in 2022. Total medical device sales accelerated from CHF 9.0 million to CHF 21.3 million The Medical Devices segment achieved a positive EBITDA of CHF 3.8 million driven by MagnetOs Cash & cash equivalents amounted to CHF 14.8 million and funds available (including trade, and other receivables) totaled at CHF 21.4 million as of September 30, 2023 Transition of responsibilities in the Executive Management to emphasize the advanced commercial nature of the company: Current CEO Joost de Bruijn will refocus on the Company’s scientific, R&D…
-
Kuros Biosciences Reports Results for First Half 2023
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices rose from CHF 5.7 million to CHF 12.9 million Medical Devices segment achieved a positive EBITDA of CHF 2.2 million driven by MagnetOs Cash & cash equivalents amounted to CHF 16.9 million, funds available (including trade, and other receivables) totaled at CHF 22.0 million as of June 30, 2023 Operational Highlights Accelerated commercial roll-out of MagnetOs in the U.S. on track Key efficacy data on MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals In the first half of 2023, Kuros engaged into a limited, non-exclusive sales…
-
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to address $2.2B market opportunity Schlieren (Zurich), Switzerland, July 13, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in single-level transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease (DDD). Fibrin-PTH is a novel parathyroid hormone-based healing matrix allowing targeted, controlled bone generation. “This first-of-its-kind, drug-biologic combination product has the potential to transform the way spinal fusions are…
-
Annual General Meeting of Kuros Biosciences approves all resolutions
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the persons entrusted with the Management, voted in favor of the proposed appropriation of the Annual Results and approved the compensation for the members of the Board of Directors and the Executive Committee. Clemens van Blitterswijk was re-elected as Chairman and Joost de Bruijn, Scott P. Bruder and Oliver Walker were re-elected as members of the…
-
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million Key data on efficacy of MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals Kuros is financed to complete Phase 2 clinical study of Fibrin-PTH in spine and to accelerate commercial roll-out of MagnetOs in the U.S. Daniel Geiger appointed as Chief Financial Officer Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs rose 168% in the first three months of 2023,…
